Real-World Efficacy and Safety of Tafluprost in Primary Open-Angle Glaucoma Patients with Corneal Disorders: A Taiwan Experience

Table 3

Results of secondary endpoints at each visit.

Endpoint (mean ± SD)	Visit 0	Visit 1	Visit 2
TBUT (s)	2.9 ± 1.3	3.6 ± 1.3	4.1 ± 1.3
Change from V0	N/A	0.8 ± 1.5	1.2 ± 1.7
-value		<0.05	<0.05
Irritation/burning/stinging score	0.7 ± 1.1	0.2 ± 0.4	0.3 ± 0.6
Change from V0		−0.5 ± 1.1	−0.4 ± 1.4
-value		N/A	N/A
Itching score	0.2 ± 0.6	0.2 ± 0.6	0.2 ± 0.4
Change from V0		−0.0 ± 0.7	−0.1 ± 0.6
-value		N/A	N/A
Foreign body sensation score	0.3 ± 0.8	0.2 ± 0.6	0.2 ± 0.4
Change from V0		−0.1 ± 1.1	−0.1 ± 0.9
-value		N/A	N/A
Tearing score	0.3 ± 0.6	0.1 ± 0.5	0.2 ± 0.4
Change from V0		−0.2 ± 0.8	−0.1 ± 0.5
-value		N/A	N/A
Dry eye sensation score	0.8 ± 0.8	0.4 ± 0.7	0.3 ± 0.5
Change from V0		−0.5 ± 0.9	−0.5 ± 0.8
-value		<0.05	<0.05